Journal of Clinical Oncology, Vol 16, 2052-2059, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?

V Leblond, F Davi, F Charlotte, R Dorent, MO Bitker, L Sutton, I Gandjbakhch, JL Binet and M Raphael
Departement d'Hematologie, Hopital Pitie-Salpetriere, Paris, France. veronique.leblond@psl.ap-hp-paris.fr

PURPOSE: Organ recipients are at a high risk of posttransplant lymphoproliferative disorders (PTLD) as a result of immunosuppressive therapy. Most B-cell lymphomas are associated with Epstein-Barr virus (EBV) infection. We describe a morphologically and clinically distinct group of PTLD in 11 patients that occurred late after organ transplantation and were not associated with EBV. PATIENTS AND METHODS: There were seven kidney, three heart, and one liver transplant recipients (group I). The clinical manifestations, pathologic findings, treatment, and outcome were compared with those in 21 patients with EBV- associated PTLD treated in our institution (group II). EBV was detected with at least two techniques: Epstein-Barr-encoded RNA (EBER) in situ hybridization with EBER 1 + 2 probes, Southern blotting, and detection of latent membrane protein 1 (LMP1) expression by immunohistochemistry. RESULTS: The time between transplantation and the diagnosis of lymphoma ranged from 180 to 10,220 days in group I (mean, 2,234; median, 1,800) and from 60 to 2,100 days in group II (mean, 546; median, 180), and was significantly shorter in group II (P = .02). Among 19 tumors diagnosed within 2 years after the graft, 16 were associated with EBV; among 13 tumors diagnosed after more than 2 years, only five were associated with EBV. All of the B-cell PTLDs in group I were classified as monomorphic, meeting the criteria of B diffuse large-cell lymphoma (B- DLCL) with a component of immunoblasts, and genotyping confirmed their monoclonality. Three tumors were T-cell pleomorphic lymphomas. Tumor sites were mainly bone marrow and lymph nodes. Overall median survival was 1 month in group I and 37 months in group II, with two patients still alive in group I and nine in group II. The survival time was significantly longer in group II (P < .01). CONCLUSION: EBV-negative PTLD may be a late serious complication of organ transplantation. Half the tumors observed after kidney transplantation in our center were not associated with EBV and emerged after more than 5 years, which suggests the number of EBV-negative PTLDs in organ recipients might increase with time.

This article has been cited by other articles:

				M. J Everly, R. D Bloom, D. E Tsai, and J. Trofe Posttransplant Lymphoproliferative Disorder Ann. Pharmacother., November 1, 2007; 41(11): 1850 - 1858. [Abstract] [Full Text] [PDF]

				H. Williams and D. H. Crawford Epstein-Barr virus: the impact of scientific advances on clinical practice Blood, February 1, 2006; 107(3): 862 - 869. [Abstract] [Full Text] [PDF]

				I. M. Ghobrial, T. M. Habermann, M. J. Maurer, S. M. Geyer, K. M. Ristow, T. S. Larson, R. C. Walker, S. M. Ansell, W. R. Macon, G. G. Gores, et al. Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders J. Clin. Oncol., October 20, 2005; 23(30): 7574 - 7582. [Abstract] [Full Text] [PDF]

				T. G. Gross, J. C. Bucuvalas, J. R. Park, T. C. Greiner, S. H. Hinrich, S. S. Kaufman, A. N. Langnas, R. A. McDonald, F. C. Ryckman, B. W. Shaw, et al. Low-Dose Chemotherapy for Epstein-Barr Virus-Positive Post-Transplantation Lymphoproliferative Disease in Children After Solid Organ Transplantation J. Clin. Oncol., September 20, 2005; 23(27): 6481 - 6488. [Abstract] [Full Text] [PDF]

				C. N. Kotton and J. A. Fishman Viral Infection in the Renal Transplant Recipient J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1758 - 1774. [Abstract] [Full Text] [PDF]

				M. E. Halkos, J. I. Miller, K. P. Mann, D. L. Miller, and A. A. Gal Thoracic Presentations of Posttransplant Lymphoproliferative Disorders Chest, December 1, 2004; 126(6): 2013 - 2020. [Abstract] [Full Text] [PDF]

				D. Capello, M. Cerri, G. Muti, E. Berra, P. Oreste, C. Deambrogi, D. Rossi, G. Dotti, A. Conconi, M. Vigano, et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders Blood, November 15, 2003; 102(10): 3775 - 3785. [Abstract] [Full Text] [PDF]

				Y Sadahira, K Kumori, Y Mikami, T Otsuki, T Manabe, and K Aoyama Post-transplant malignant lymphoma with monoclonal immunoglobulin gene rearrangement and polyclonal Epstein-Barr virus episomes J. Clin. Pathol., November 1, 2001; 54(11): 887 - 889. [Abstract] [Full Text] [PDF]

				I. Molnar and Y.-K. Keung Treatment of post-transplant lymphoproliferative disorder with rituximab and radiation in a patient with second renal allograft Nephrol. Dial. Transplant., October 1, 2001; 16(10): 2114 - 2115. [Full Text] [PDF]

				C. L. Moertel, B. Carlson-Green, J. Watterson, and S. C. Simonton Lymphomatoid Granulomatosis After Childhood Acute Lymphoblastic Leukemia: Report of Effective Therapy Pediatrics, May 1, 2001; 107(5): 82e - 82. [Abstract] [Full Text]

				M. L. Gulley Molecular Diagnosis of Epstein-Barr Virus-Related Diseases J. Mol. Diagn., February 1, 2001; 3(1): 1 - 10. [Abstract] [Full Text]

				M-F. Mamzer-Bruneel, C. Lome, E. Morelon, V. Levy, P. Bourquelot, F. Jacobs, A. Gessain, E. Mac Intyre, N. Brousse, H. Kreis, et al. Durable Remission After Aggressive Chemotherapy for Very Late Post-Kidney Transplant Lymphoproliferation: A Report of 16 Cases Observed in a Single Center J. Clin. Oncol., November 1, 2000; 18(21): 3622 - 3632. [Abstract] [Full Text] [PDF]

				P. B. Sagireddy, P. E. Pergola, D. J. Riley, D. H. Boldt, and B. S. Kasinath Non-clonal large granular cell lymphocytosis after renal transplantation Nephrol. Dial. Transplant., September 1, 2000; 15(9): 1485 - 1486. [Full Text] [PDF]

				A. Martin, F. Baran-Marzak, S. El Mansouri, C. Legendre, V. Leblond, F. Charlotte, F. Davi, D. Canioni, and M. Raphael Expression of p16/INK4a in Posttransplantation Lymphoproliferative Disorders Am. J. Pathol., May 1, 2000; 156(5): 1573 - 1579. [Abstract] [Full Text] [PDF]

				T. Greiner, J. O. Armitage, and T. G. Gross Atypical Lymphoproliferative Diseases Hematology, January 1, 2000; 2000(1): 133 - 146. [Abstract] [Full Text] [PDF]

				R. E. Curtis, L. B. Travis, P. A. Rowlings, G. Socie, D. W. Kingma, P. M. Banks, E. S. Jaffe, G. E. Sale, M. M. Horowitz, R. P. Witherspoon, et al. Risk of Lymphoproliferative Disorders After Bone Marrow Transplantation: A Multi-Institutional Study Blood, October 1, 1999; 94(7): 2208 - 2216. [Abstract] [Full Text] [PDF]